A retrospective study of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancer patients
Latest Information Update: 31 Jul 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Jul 2021 Results published in the Oncologist
- 25 May 2021 New trial record
- 12 Apr 2021 Results published in the BMC Cancer